Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.67 |
| ▸ | CTSG | P08311 | 1/20 | 0.67 |
| ▸ | CMA1 | P23946 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20943188 | 1.00 | ELANE (0.67) | ELANECTSGCMA1 | |
| SCHEMBL20943154 | 1.00 | ELANE (0.67) | ELANECTSGCMA1 | |
| SCHEMBL30583172 | 1.00 | ELANE (0.67) | ELANECTSGCMA1 | |
| SCHEMBL3935567 | 1.00 | ELANE (0.67) | ELANECTSGCMA1 | |
| SCHEMBL20943157 | 0.94 | ELANE (0.60) | ELANECTSGCMA1 | |
| SCHEMBL20943159 | 0.94 | ELANE (0.60) | ELANECTSGCMA1 | |
| SCHEMBL7310232 | 0.92 | ELANE (0.80) | ELANECTSGCMA1 | |
| SCHEMBL20943149 | 0.91 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL20943178 | 0.91 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL29601531 | 0.91 | ELANE (0.63) | ELANECTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4008304-B1 | EXTERNAL PREPARATION FOR SKIN FOR WRINKLE IMPROVEMENT | POLA CHEM IND INC (JP) | 2025-07-23 | — | — | EP | claimed |
| US-11413224-B2 | External preparation for skin for wrinkle improvement | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2022-08-16 | — | — | US | claimed |
| EP-4008304-A2 | EXTERNAL PREPARATION FOR SKIN FOR WRINKLE IMPROVEMENT | Pola Chemical Industries Inc. (JP) | 2022-06-08 | — | — | EP | claimed |
| EP-3476381-B1 | EXTERNAL PREPARATION FOR SKIN FOR WRINKLE IMPROVEMENT | POLA CHEM IND INC (JP) | 2021-12-22 | — | — | EP | claimed |
| CN-113693965-A | External preparation for skin for improving wrinkles | 宝丽化成工业有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-109310585-B | External preparation for skin for improving wrinkles | 宝丽化成工业有限公司 | 2021-10-29 | — | — | CN | claimed |
| US-20210030631-A1 | EXTERNAL PREPARATION FOR SKIN FOR WRINKLE IMPROVEMENT | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2021-02-04 | — | — | US | claimed |
| EP-1057491-B1 | Preventives/remedies for skin aging | ASTELLAS PHARMA INC (JP) | 2013-06-19 | — | — | EP | claimed |
| WO-2006070012-A1 | AGENTS USEFUL IN TREATING INFLAMMATORY BOWEL DISEASE | INGENIUM PHARMACEUTICALS AG (DE) | 2006-07-06 | — | — | WO | claimed |
| EP-0494071-B1 | Trifluoromethylketone tripeptide derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-04-16 | — | — | EP | claimed |
| US-5430025-A | Elastase-inhibiting peptides bearing a C-terminal trifluoromethylketone moiety | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | claimed |
| US-5296591-A | Enzyme inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | claimed |
| EP-0494071-A2 | Trifluoromethylketone tripeptide derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-08 | — | — | EP | claimed |
| US-11413224-B2 | External preparation for skin for wrinkle improvement | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-4008304-A2 | EXTERNAL PREPARATION FOR SKIN FOR WRINKLE IMPROVEMENT | Pola Chemical Industries Inc. (JP) | 2022-06-08 | — | — | EP | disclosed |
| EP-3476381-B1 | EXTERNAL PREPARATION FOR SKIN FOR WRINKLE IMPROVEMENT | POLA CHEM IND INC (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-0494071-B1 | Trifluoromethylketone tripeptide derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-04-16 | — | — | EP | disclosed |
| US-5430025-A | Elastase-inhibiting peptides bearing a C-terminal trifluoromethylketone moiety | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| US-5296591-A | Enzyme inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| EP-0494071-A2 | Trifluoromethylketone tripeptide derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030631-A1 | EXTERNAL PREPARATION FOR SKIN FOR WRINKLE IMPROVEMENT | F12, CUTA, SQLE | ELANE 137/4885CTSG 3268/4885CMA1 915/4885 |
| US-11413224-B2 | External preparation for skin for wrinkle improvement | F12, CUTA, SQLE | ELANE 137/4885CTSG 3268/4885CMA1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.